David Paul Insider Sale for 827,004 Shares of Globus Medical, Inc. (GMED); Sterling Capital Management Boosted Edwards Lifesciences Com (EW) Holding

Globus Medical, Inc. (NYSE:GMED) Logo

Sterling Capital Management Llc increased Edwards Lifesciences Corp Com (EW) stake by 55.33% reported in 2017Q4 SEC filing. Sterling Capital Management Llc acquired 14,027 shares as Edwards Lifesciences Corp Com (EW)’s stock rose 22.78%. The Sterling Capital Management Llc holds 39,378 shares with $4.44 million value, up from 25,351 last quarter. Edwards Lifesciences Corp Com now has $26.85 billion valuation. The stock decreased 1.49% or $1.93 during the last trading session, reaching $127.36. About 1.52M shares traded or 10.94% up from the average. Edwards Lifesciences Corporation (NYSE:EW) has risen 44.06% since May 1, 2017 and is uptrending. It has outperformed by 32.51% the S&P500.

The stock decreased 1.04% or $0.54 during the last trading session, reaching $51.19. About 915,627 shares traded or 39.88% up from the average. Globus Medical, Inc. (NYSE:GMED) has risen 65.36% since May 1, 2017 and is uptrending. It has outperformed by 53.81% the S&P500.

Analysts await Globus Medical, Inc. (NYSE:GMED) to report earnings on May, 2. They expect $0.36 earnings per share, up 12.50% or $0.04 from last year’s $0.32 per share. GMED’s profit will be $34.98M for 35.55 P/E if the $0.36 EPS becomes a reality. After $0.38 actual earnings per share reported by Globus Medical, Inc. for the previous quarter, Wall Street now forecasts -5.26% negative EPS growth.

Since December 13, 2017, it had 0 buys, and 7 insider sales for $20.63 million activity. Another trade for 3,076 shares valued at $120,893 was made by Payne Steven on Friday, December 15. $1.20 million worth of Globus Medical, Inc. (NYSE:GMED) was sold by Schwartz Eric on Wednesday, March 28. On Monday, April 9 the insider Scavilla Daniel T sold $5.00 million. Demski David M had sold 149,109 shares worth $7.60M. On Wednesday, December 13 Williams Anthony L sold $574,491 worth of Globus Medical, Inc. (NYSE:GMED) or 15,000 shares. On Thursday, March 8 the insider Davidar David D sold $3.54 million.

Among 15 analysts covering Globus Medical Inc (NYSE:GMED), 9 have Buy rating, 2 Sell and 4 Hold. Therefore 60% are positive. Globus Medical Inc has $6000 highest and $21 lowest target. $43.11’s average target is -15.78% below currents $51.19 stock price. Globus Medical Inc had 49 analyst reports since August 3, 2015 according to SRatingsIntel. Oppenheimer maintained Globus Medical, Inc. (NYSE:GMED) rating on Friday, May 5. Oppenheimer has “Hold” rating and $32 target. The firm has “Equalweight” rating by Barclays Capital given on Wednesday, July 27. On Wednesday, November 9 the stock rating was downgraded by Oppenheimer to “Perform”. As per Tuesday, January 2, the company rating was upgraded by Morgan Stanley. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, July 18 report. Piper Jaffray maintained Globus Medical, Inc. (NYSE:GMED) on Thursday, August 17 with “Buy” rating. The firm has “Hold” rating by Needham given on Tuesday, September 26. The firm has “Buy” rating given on Tuesday, January 2 by Piper Jaffray. The stock has “Hold” rating by Oppenheimer on Wednesday, August 30. The firm has “Buy” rating by Canaccord Genuity given on Thursday, January 4.

Recently, a huge insider trading sale was made. David Paul, the Executive Chairman and an insider of Globus Medical Inc unloaded precisely 827,004 shares of Globus Medical Inc, worth about $42,843,633 US Dollars, at $51.8 for every share at the time of the sale. David Paul has rights to roughly 10%+ of Globus Medical Inc’s stock market cap or 612,712 shares. Considering the size of the deal, it is difficult to stay unseen.

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company has market cap of $4.97 billion. The firm offers products that address an array of spinal pathologies, anatomies, and surgical approaches. It has a 46.54 P/E ratio. It provides fusion products that are used in cervical, thoracolumbar, sacral, and interbody/corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions.

Investors sentiment decreased to 0.99 in 2017 Q4. Its down 0.39, from 1.38 in 2017Q3. It fall, as 26 investors sold Globus Medical, Inc. shares while 83 reduced holdings. 40 funds opened positions while 68 raised stakes. 59.89 million shares or 7.54% less from 64.77 million shares in 2017Q3 were reported. Fny Managed Accounts Ltd stated it has 81 shares. Price T Rowe Associates Md has invested 0% in Globus Medical, Inc. (NYSE:GMED). 11,632 are held by Bancshares Of Montreal Can. 10,337 were reported by Amalgamated National Bank. Hussman Strategic Advsrs invested in 50,000 shares or 0.59% of the stock. First Citizens National Bank & Co holds 7,692 shares. Ngam Advsrs Limited Partnership holds 0.01% of its portfolio in Globus Medical, Inc. (NYSE:GMED) for 24,849 shares. Wellington Mgmt Grp Inc Limited Liability Partnership invested in 0.06% or 6.70M shares. Blair William & Il reported 12,380 shares. Schroder Invest Group Incorporated has 146,900 shares. California Employees Retirement System invested in 0% or 89,605 shares. Crow Point Prns Ltd Liability Corporation holds 1,320 shares. Janney Montgomery Scott Ltd accumulated 0.01% or 28,015 shares. Stratos Wealth Limited holds 167 shares. Guggenheim Capital Limited Co holds 223,176 shares or 0.02% of its portfolio.

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 21 have Buy rating, 1 Sell and 6 Hold. Therefore 75% are positive. Edwards Lifesciences Corp had 112 analyst reports since July 30, 2015 according to SRatingsIntel. SunTrust maintained Edwards Lifesciences Corporation (NYSE:EW) on Monday, March 7 with “Neutral” rating. The firm has “Buy” rating by BTIG Research given on Monday, April 4. The rating was maintained by Morgan Stanley on Friday, February 2 with “Overweight”. The firm has “Buy” rating by Jefferies given on Thursday, February 1. As per Thursday, February 1, the company rating was maintained by Cowen & Co. The stock has “Outperform” rating by Cowen & Co on Wednesday, April 27. The firm has “Buy” rating by Canaccord Genuity given on Thursday, February 15. Deutsche Bank maintained the shares of EW in report on Thursday, October 26 with “Hold” rating. The firm earned “Buy” rating on Wednesday, July 27 by BTIG Research. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Buy” rating given on Thursday, February 1 by Canaccord Genuity.

Globus Medical, Inc. (NYSE:GMED) Institutional Positions Chart